Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study

被引：8
|
作者：
Moreau, Philippe [1 ]
Ghori, Razi [2 ]
Farooqui, Mohammed [2 ]
Marinello, Patricia [2 ]
San Miguel, Jesus [3 ]
机构：
[1] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France
[2] Merck & Co Inc, Dept Med Oncol, Kenilworth, NJ USA
[3] Clin Univ Navarra, CIMA, IDISNA, CIBERONC,Dept Clin & Translat Med, Pamplona, Spain
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 194卷 / 01期
关键词：
multiple myeloma; immunotherapy; oncology; IMMUNOTHERAPY;
D O I：
10.1111/bjh.17448
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E48 / E51
页数：4
相关论文
共 50 条
  • [1] Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study
    Mateos, Maria-Victoria
    Orlowski, Robert Z.
    Ocio, Enrique M.
    Rodriguez-Otero, Paula
    Reece, Donna
    Moreau, Philippe
    Munshi, Nikhil
    Avigan, David E.
    Siegel, David S.
    Ghori, Razi
    Farooqui, Mohammed Z. H.
    Marinello, Patricia
    San-Miguel, Jesus
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (05) : E117 - E121
  • [2] Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023
    San Miguel, Jesus
    Mateos, Maria-Victoria
    Shah, Jatin J.
    Ocio, Enrique M.
    Rodriguez-Otero, Paula
    Reece, Donna
    Munshi, Nikhil C.
    Avigan, David
    Ge, Yang
    Balakumaran, Arun
    Marinello, Patricia
    Orlowski, Robert Z.
    Siegel, David
    BLOOD, 2015, 126 (23)
  • [3] PEMBROLIZUMAB PLUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY AND BIOMARKER RESULTS FROM THE PHASE 1 KEYNOTE-023 STUDY
    Otero, P. Rodriguez
    Mateos, M-V.
    Orlowski, R.
    Siegel, D.
    Reece, D.
    Moreau, P.
    Ocio, E. M.
    Munshi, N.
    Avigan, D.
    Ghori, R.
    Wnek, R.
    Mogg, R.
    Marinello, P.
    Miguel, J. San
    HAEMATOLOGICA, 2017, 102 : 319 - 319
  • [4] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Badros, Ashraf
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander
    Dogan, Ahmet
    Rapoport, Aaron P.
    Kocoglu, Mehmet
    Lederer, Emily
    Philip, Sunita
    Milliron, Todd
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2017, 130 (10) : 1189 - 1197
  • [5] Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study
    Ocio, E. M.
    Shah, J.
    Jagannath, S.
    Mateos, M-V
    Palumbo, A.
    Kher, U.
    Marinello, P.
    San Miguel, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
    Derman, Benjamin A.
    Chari, Ajai
    Zonder, Jeffrey
    Major, Ajay
    Stefka, Andrew T.
    Jiang, Ken
    Karrison, Theodore
    Jasielec, Jagoda
    Jakubowiak, Andrzej
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (05) : 564 - 570
  • [7] Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)
    Atrash, Shebli
    Robinson, Myra
    Bhutani, Manisha
    Zonder, Jeffrey A.
    Friend, Reed
    Paul, Barry
    Auclair, Daniel
    Robinsons, Jordan
    Ndiaye, Ami P.
    Bumgarner, Kelly
    Norek, Sarah
    Symanowski, James T.
    Voorhees, Peter M.
    Usmani, Saad Z.
    BLOOD, 2019, 134
  • [8] Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
    Sara Bringhen
    Roberto Mina
    Anna Maria Cafro
    Anna Marina Liberati
    Stefano Spada
    Angelo Belotti
    Gianluca Gaidano
    Francesca Patriarca
    Rossella Troia
    Renato Fanin
    Lorenzo De Paoli
    Giuseppe Rossi
    Alessandra Lombardo
    Paola Bertazzoni
    Antonio Palumbo
    Pieter Sonneveld
    Mario Boccadoro
    Leukemia, 2018, 32 : 1803 - 1807
  • [9] Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
    Bringhen, Sara
    Mina, Roberto
    Cafro, Anna Maria
    Liberati, Anna Marina
    Spada, Stefano
    Belotti, Angelo
    Gaidano, Gianluca
    Patriarca, Francesca
    Troia, Rossella
    Fanin, Renato
    De Paoli, Lorenzo
    Rossi, Giuseppe
    Lombardo, Alessandra
    Bertazzoni, Paola
    Palumbo, Antonio
    Sonneveld, Pieter
    Boccadoro, Mario
    LEUKEMIA, 2018, 32 (08) : 1803 - 1807
  • [10] Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    Salcedo, Meghan
    Lendvai, Nikoletta
    Mastey, Donna
    Schlossman, Julia
    Hultcrantz, Malin
    Korde, Neha
    Mailankody, Sham
    Lesokhin, Alexander
    Hassoun, Hani
    Smith, Eric
    Shah, Urvi
    Diab, Victoria
    Werner, Kelly
    Landau, Heather
    Lahoud, Oscar
    Drullinsky, Pamela
    Shah, Gunjan
    Chung, David
    Scordo, Michael
    Giralt, Sergio
    Landgren, Ola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (03): : 198 - 200
12345